AI Summary

Researchers at Moffitt Cancer Center have made a significant discovery in the field of prostate cancer treatment. They have developed three mathematical biomarkers that can help physicians tailor therapy to individual patients. These biomarkers are calculated from routine prostate-specific antigen (PSA) blood tests, which are commonly used to monitor prostate cancer. The biomarkers can potentially predict treatment outcomes early in the treatment process. The development of these biomarkers may allow for more effective and personalized treatment of prostate cancer, as physicians can adjust therapy based on individual patient responses.

AI summaries can be wrong sometimes—always verify important details using the source article.